Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE (0.35%), DAX (0.42%), CAC40 (0.34%)

Jul 15 ,2026

  • Synopsis

    • European equity markets are set for a negative open amidst higher Asian equities Wednesday. Semis/memory driving outperformance of South Korea and Taiwan benchmarks. Hong Kong leading China markets with cloud services providers and LLM stocks rallying. Japan picking up gains. US contracts firming afterhours.

    • In central banks, Italy central bank's Panetta speech at 10:40CET at the Annual Meeting of the Members of the Italian Banking Assn. Bundesbank's Theurer panellist at 17:00CET at event orgainised by ikf-impulse and Nagel speech at 18:00 title 'The Euro in a Fragmented World: Stability, Sovereignty, and Global Responsibility' at event organised by Club of Hohenheim.

    • At 12noon CET, Chancellor Merz will, ahead of the parliamentary summer recess, answer journalists' questions on current domestic and foreign policy issues at the Federal Press Conf. In the UK, after MPs questions on Scotland, there's weekly PMQs (likely Starmer's last) at 12noon BST, also opposition day debate (topic tbc), whilst committee topics include pre-appointment hearing with the government's preferred candidate for Chair of the OBR, Jonathan Haskel, at 9:45 and again at 14:15, regulation of the consumer insurance market at 10:00 and HM Treasury and the economics of climate and nature at 14:30.

    • Spain's ANFAC will present its 2025 Annual Report at 11:00CET (Zoom registration link).

    • Macro data sees Spain Jun final CPI, Eurozone May industrial production and Sweden Jun final CPI.

    • A busy earnings front kicked off with Benelux region names ASML Holding (ASML.NA) and TomTom (TOM2.NA). From the DACHs region, Richemont (CFR.SW) and DocMorris (DOCM.SW) updated investors. In the Nordics, Storebrand (STB.NO), Svenska Handelsbanken (SHB.A.SS), Mowi (MOWI.NO), Skandinaviska Enskilda Banken (SEB.A.SS), Elisa (ELISA.FH), Scandic Hotels Group (SHOT.S) and Aker BP (AKRBP.NO). Rio Tinto (RIO.LN) reported Q2 production overnight.

  • Top company news

    • Earnings/updates

      • Benelux:

        • NSI.NA (NSI) -- reports H1 EPRA EPS €0.79 vs year-ago €0.99; maintains interim dividend; announces share buyback programme of up to 5% of outstanding shares; lowers FY EPRA EPS outlook

        • BAR.BB (Barco) -- reports H1 net income (€4.8M) vs year-ago €23.3M; guides FY26

        • ASML.NA (ASML Holding) - reports Q2 EPS €7.59 vs consensus €6.87; guides Q3 and raises FY26 guidance

        • TOM2.NA (TomTom) -- reports Q2 net result €7.2M vs consensus €5M; reiterates FY26 guidance for both revenue and operating margin

      • DACHs:

        • CFR.SW (Richemont) -- reports Q1 revenue €6.33B vs StreetAccount €5.96B

        • DOCM.SW (DocMorris) -- reports prelim. Q2 revenue CHF295.4M vs FactSet CHF286.1M [2 est, CHF281-291.1M]; Adj EBITDA is expected to improve further q/q

        • HPHA.GR (Heidelberg Pharma) -- reports H1 EPS (€0.07) vs year-ago (€0.27)

      • Nordics:

        • STB.NO (Storebrand) -- reports Q2 cash equivalent earnings after tax NOK1.38B vs consensus NOK1.15B; share buyback programme of NOK 1B initiated today

        • AXFO.SS (Axfood) -- reports Q2 EPS SEK2.97 ex-items vs FactSet SEK3.19 [8 est, SEK3.08-3.38]

        • PUBLI.NO (Ppi Public Property Invest) -- reports Q2 EPS (SEK0.06) vs FactSet SEK0.35 [4 est, SEK0.27-0.40]

        • NEL.NO (NEL) -- reports Q2 net loss (NOK189M) vs FactSet (NOK115M) [3 est, (NOK194)-(66M)] (unclear if comparable)

        • SHB.A.SS (Svenska Handelsbanken) -- reports Q2 EPS SEK2.60 vs FactSet SEK2.75 [13 est, SEK2.52-2.83]

        • MOWI.NO (Mowi) -- Q2 trading update: operational EBIT €231M vs FactSet €212.1M [13 est, €192-270.8M]

        • CAMX.SS (Camurus) -- reports Q2 EPS SEK4.05 vs FactSet SEK3.23 [5 est, SEK2.63-3.80]

        • AKRBP.NO (Aker BP) -- reports Q2 EPS $0.82 vs FactSet $0.94 [9 est, $0.88-1.15]

        • SEB.A.SS (Skandinaviska Enskilda Banken) -- reports Q2 EPS SEK4.44 vs StreetAccount SEK3.90

        • PNDX.B.SS (Pandox) -- reports Q2 cash EPS SEK3.48 vs FactSet SEK3.42 [5 est, SEK3.20-3.70]

        • AFRY.SS (AFRY AB) -- reports Q2 EPS SEK1.71 vs FactSet SEK2.35 [5 est, SEK1.71-2.80]

        • CDON.SS (CDON) -- reports Q2 adjusted EPS (SEK0.98) vs year-ago (SEK0.44)

        • ENEA.SS (Enea) -- reports Q2 EPS SEK0.66 vs FactSet SEK0.80 [1 est]

        • SVED.B.SS (Svedbergs Group ) --reports Q2 EPS SEK0.78 vs FactSet SEK1.03 [3 est, SEK1.00-1.10]

        • SHOT.SS (Scandic Hotels Group) -- reports Q2 EPS SEK2.01 ex-items vs FactSet SEK2.01 [3 est, SEK1.54-2.40]; expects strong Q3

        • CLA.B.SS (Cloetta) -- reports Q2 EPS SEK0.77 vs FactSet SEK0.65 [2 est, SEK0.65-0.65]

        • ELISA.FH (Elisa) -- reports Q2 comparable EPS €0.59 vs FactSet €0.59 [11 est, €0.56-0.63]

        • COOR.SS (Coor Service Management Holding) -- reports Q2 EPS SEK0.9 vs FactSet SEK1.08 [2 est, SEK1.07-1.10]

        • NETI.B.SS (Net Insight) -- reports Q2 EPS (SEK0.09) vs year-ago (SEK0.03); confirms preliminary numbers

        • INWI.SS (Inwido) -- reports Q2 EPS SEK3.40 vs FactSet SEK3.03 [5 est, SEK2.71-3.47]

        • ELAN.B.SS (Elanders) -- reports Q2 EPS SEK0.54 ex-items vs FactSet SEK1.02 [2 est, SEK0.72-1.31]

      • UK:

        • RIO.LN (Rio Tinto) -- reports Q2 global iron ore production 100% (Mt) 87.1 vs StreetAccount 89.6

    • M&A

      • DHER.GR (Delivery Hero) -- confirms advanced negotiations with Uber Technologies in respect to potential takeover offer

      • LION (Lionsgate Studios Corp.) -- Lionsgate Studios Corp.trading higher after hours on takeover interest from Bollore Group and Banijay - Reuters

      • ARX.CN (ARC Resources) -- shareholders vote in favor of previously announced plan of arrangement to be acquired by Shell

    • Healthcare

      • REGN (Regeneron) -- FDA grants orphan drug designation to dupilumab (Dupixent) for Netherton syndrome

      • ROP.SW (Roche Holding) -- FDA Grants Priority Review to Genentech's Gazyva for Adults With Primary Membranous Nephropathy

      • ORIC (Oric Pharmaceuticals) -- announces initiation of Himalayas-1 Phase 3 trial in mCRPC evaluating rinzimetostat in combination with NUBEQA

      • MOLN.SW (Molecular Partners) -- showcases Bispecific Radio-DARPins at Gordon Research Conf

      • +BOEHRINGER (Boehringer Ingelheim) -- FDA approves first generics of Boehringer Ingelheim's Gilotrif

    • Other

      • ALFOR.FP (Forsee Power) -- enters into exclusive negotiations with FCAP for an investment to accelerate its development

      • SKA.B.SS (Skanska) -- builds new university campus in Kristianstad for about SEK 1B

      • VH2.GR (Friedrich Vorwerk) -- secures major contract as part of jv to build H2Coastlink 1 hydrogen pipeline; contract valued in double-digit millions of euros

      • KTN.GR (Kontron) -- receives major order worth nearly €100M by extending existing framework agreement with European railway operator

      • ENR.GR (Siemens Energy) -- Follow-up: Siemens Energy begins preparations for the launch of an independent brand under the name Omterra (earlier)

      • ENR.GR (Siemens Energy) -- wants to rebrand and change name ahead of schedule -- Handelsblatt

      • INW.IM (Infrastrutture Wireless Italiane) -- Inwit to file appeal against the ruling of the court of Milan on the FASTWEB case

      • ARCHION prices 787.9M-share secondary offering (for holders) at ¥250-300/share

  • Key rating changes

    • Upgrades

      • WRT1V.FH (Wartsila) -- to reduce from sell at Inderes

      • HMS.SS (HMS Networks) -- to buy from hold at Handelsbanken

      • IMB.LN (Imperial Brands) -- to buy from neutral at BofA

      • MYCR.SS (Mycronic) -- to buy from hold at DNB Carnegie

    • Downgrades

      • SAND.SS (Sandvik) -- to hold from buy at Kepler Cheuvreux

      • BofA downgrades BBVA.SM, UNI.SM

      • TYRES.FH (Nokian Renkaat) -- to sell from reduce at Inderes

      • GL9.ID (Glanbia) -- to neutral from outperform at Oddo

    • Initiations

      • BFSA.GR (Befesa) -- initiated buy at Stifel

      • DIE.BB (D'Ieteren Group) -- buy at Deutsche Bank

      • SVS.LN (Savills) -- buy at Berenberg

  • Data

    • Nikkei +1.18% to 68540.70

    • Hang Seng +1.57% to 24723.84

    • Shanghai Composite +0.03% to 3968.26

    • S&P futures +15.8 vs prior close of 7591.3

    • €-$ +0.0020 or +0.18% to 1.1443

    • $-¥ (0.05) or (0.03%) to 162.21

    • €-¥ +0.28 or +0.15% to 185.60

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.